榮昌生物-B(09995.HK)與Seagen訂立許可協議以開發及商業化維迪西妥單抗
格隆匯8月9日丨榮昌生物-B(09995.HK)發佈公吿,公司與Seagen Inc.訂立獨家全球許可協議,以開發及商業化維迪西妥單抗。根據許可協議(其中包括),Seagen獲授獨家許可,在保留為榮昌生物地區的國家以外的全球其他國家(“Seagen地區”)開發及商業化抗HER2抗體藥物偶聯物(ADC)維迪西妥單抗(RC48,商品名:愛地希®)。榮昌生物地區包括大中華區、亞洲所有其他國家(日本、新加坡除外)。
根據許可協議及在其條款及條件的規限下,公司將收取首付款2億美元及最多為24億美元的里程碑付款。除此之外,Seagen亦將向公司支付根據維迪西妥單抗在Seagen地區銷售的金額計算的特許權使用費,收取金額為產品累計銷售淨額的高個位數至百分之十幾的比例提成。
籤立協議後,在許可協議所載條款及條件的規限下,Seagen須負責承擔正在Seagen地區進行的以及未來將進行的所有臨牀試驗、開發及註冊事宜相關活動的所有成本,而公司將負責承擔出資Seagen地區以外國家應占的全球合作試驗部分。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.